Skip to main content

Table 3 Costs of pharmacotherapy

From: Economic burden of osteoporotic fractures in Austria

Drug Brand Name(Austria) % patients with osteoporotic fracture (n = 119.911) Total number of patients treated Annual cost of treatment per capita3 Total costs
Alendronate Fosamax 10 mg® 2.4% 1 2,878 321.0 923,838
  Fosamax 70 mg® 6.7%1 8,034 213.0 1,711,242
  Generic Alendronate 70 mg (e.g. Alendronstad®) 2.9% 1 3,477 205.2 713,480
   {Total:12.0%}    
Ibandronate Bonviva 3 mg® 3.6%2 4,316 456.4 1,969,822
Risedronate Actonel 5 mg® 0.5%2 600 438.6 263,160
  Actonel 35 mg® 3.1%2 3,717 490.2 1,821,330
   {Total: 3.6%}    
Zoledronate Aclasta 5 mg® 1.4% 1,679 303.1 508,905
Raloxifene Evista 60 mg® 0.4% 480 438.6 210,528
Strontium Ranelate Protelos 2 g® 0.4% 480 570.6 273,888
Parathyroid-hormone Forsteo®/Preotact® 0.6% 720 4,867.64 3,504,672
Calcitonin (nasal-spray) Calcitonin Novartis Nasal Spray® 0.4% 480 639.0 306,720
Total   22.4% 26,861 --- 12,207,585
Analgesics NSAR (e.g. Diclofenac 50 mg®) 37% 44,367 75.6 3,354,145
Calcium (1000 mg) + Vit D (800 IU) e.g. Cal-d-Vita® (500 mg/800 IU) 24.3%5 29,138 75.0 2,185,3505
      5,539,495
     Total 17,747.080
  1. 1 Estimated proportions of Fosamax daily, once-weekly, and generic forms according to data provided by IMS.
  2. 2 Estimated proportions of Actonel daily vs once-weekly forms according to data provided by IMS.
  3. 3 Annual cost of treatment according to version 10 (Oct.) of the Austrian EKO (Erstattungskodex) 2008.
  4. 4 Forsteo® + Preotact® (mean value applied).
  5. 5 Without patients who are receiving alendronate or risedronate (calcium + vitamin D tablets already included in price).